Financials › Capital Markets
Coinbase Global
- Ticker
- COIN
- Exchange
- NASDAQ
- Sector
- Financials
- Industry
- Capital Markets
Price data arrives in a later stage, so no price is shown yet.
Latest news
Company newsCOIN
Explain this story: TechCrunch Disrupt 2026: Blackstone’s Jas Khaira on building the next generation of AI giants
Jas Khaira, global head of Blackstone N1, will speak at TechCrunch Disrupt 2026 about building lasting AI companies. He will discuss how Blackstone evaluates firms, the role of capital in scaling, and what differentiates enduring businesses from those with fleeting momentum. The event highlights the significant capital requirements for AI infrastructure and talent, as evidenced by recent Blackstone investments in companies like Neysa and Anthropic's Ode.
OtherYahoo FinanceSector and industry: FinancialsCapital MarketsTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Jas Khaira, global head of Blackstone N1, will speak at TechCrunch Disrupt 2026 about building lasting AI companies. He will discuss how Blackstone evaluates firms, the role of capital in scaling, and what differentiates enduring businesses from those with fleeting momentum. The event highlights the significant capital requirements for AI infrastructure and talent, as evidenced by recent Blackstone investments in companies like Neysa and Anthropic's Ode.
This describes the words the journalist used. It is not a prediction, and not advice.
ImportantINTC
Explain this story: Intel Stocks Gain 2.1% as High-NA Enters Production
Intel's stock gained 2.1% after its High-NA chipmaking program, in collaboration with ASML, moved beyond qualification into production for certain layers of Panther Lake processors. While this technical progress strengthens Intel's position in the foundry market, investors are awaiting evidence of competitive yields, disciplined spending, and significant customer orders to justify the current stock valuation, which is significantly above its GF Value estimate. The company still needs to demonstrate a clear business payoff from this manufacturing hurdle.
Other
ImportantGOOGL
Explain this story: How Much Must Google Cloud Be Worth to Justify Alphabet’s Valuation?
This article examines how much Google Cloud's value contributes to Alphabet's overall valuation, given its rapid growth and operating income. It uses a sum-of-parts sensitivity analysis with hypothetical multiples to estimate Cloud's impact on Alphabet's $4.09 trillion enterprise value. The analysis highlights that while Cloud's growth is significant, the durability of Search and other Services, along with continued infrastructure spending and margin persistence, remain crucial for Alphabet's investment case.
Other
ImportantMS
Explain this story: Morgan Stanley Commits $684M to Uptown Dallas Regional Hub
Morgan Stanley is investing $684 million to establish a regional hub in Uptown Dallas, following in the footsteps of Goldman Sachs. The firm will temporarily occupy space at Fountain Place until 2031, after which it will move into a newly constructed 700,000-square-foot tower at 2401 McKinney Ave, aiming to employ 3,800 people by 2035. This significant investment, supported by state and city incentives, cements Uptown Dallas as a prime financial services hub.
Other
ImportantAMAT
Explain this story: Morgan Stanley resets AMAT stock price target by $79
Morgan Stanley has revised its price target for Applied Materials (AMAT) down to $563 from $642, despite raising its 2027 revenue and EPS forecasts due to increased NAND demand. The cut reflects a lowered valuation multiple from 26x to 22x, as the firm believes the stock's current price already accounts for much of the positive business outlook. Despite the price target reduction, it still suggests a 33% upside from its current trading price, with AMAT having seen significant year-to-date and year-over-year gains.
Other
Company newsMRNA
Explain this story: Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week
Moderna (MRNA) shares surged to a three-year high in anticipation of upcoming pipeline updates, particularly at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum. The company is expected to present further Phase 3 trial data for its melanoma treatment candidate, intismeran autogene combined with Merck’s Keytruda, which previously showed positive results in recurrence-free and distant metastasis-free survival. This news highlights the potential of its mRNA-based cancer therapy in a large addressable market, increasing investor confidence despite a slight decrease in the number of hedge funds holding the stock.
Other
Elsewhere
These links open other websites. We do not provide price data yet.